Retail price regulation and innovation: Reference pricing in the pharmaceutical industry

Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical innovation, health and expenditures. The model is based on a dynamic game involving three types of agents: pharmaceutical firms, consumers and a regulatory entity. Pharmaceutical firms choose the level of research investment and its innovative content, then negotiate introductory prices for new drugs with the regulator. Reference pricing affects negatively the intensity of research and it also modifies the types of innovations that are brought to the market, deterring small innovations. The model is calibrated with a small data on statins in France. Our results suggest that reference pricing typically generates a decline in health, whereas discounted expenditures may decrease or increase, depending on the degree of deterrence of cost reducing innovations. © 2009 Elsevier B.V.

• Fecha de publicación: 2010
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/22361
• Acceso en línea: https://doi.org/10.1016/j.jhealeco.2009.11.015; https://repository.urosario.edu.co/handle/10336/22361
• Palabra clave: Atorvastatin; Fluindostatin; Hydroxymethylglutaryl coenzyme a reductase inhibitor; Pravastatin; Rosuvastatin; Simvastatin; Drug; Health expenditure; Industrial regulation; Innovation; Modeling; Pharmaceutical industry; Pricing policy; Retailing; Article; Drug cost; Drug industry; Dynamics; Health care cost; Human; Mathematical analysis; Pharmaceutical care; Welfare; Biomedical research; Drug costs; Drug industry; France; Innovation; Me-too; Pharmaceutical laboratories; Reference pricing; investigational; theoretical; economic; Drugs; Models; Models
• License: Abierto (Texto Completo)